Dan Clevenger


I help companies at all stages of development navigate complex transactional and disclosure matters.

Dan Clevenger helps technology, energy and cleantech, and life sciences companies at all stages of growth, as well as their boards, as they navigate the legal, regulatory, governance and business hurdles companies face in the current market.

Over his 20+ year career, Dan has partnered with high-growth companies on a wide range of strategic transactions and matters, including public offerings of debt and equity securities, venture capital investments, and mergers and acquisitions. Dan has a particular interest in the energy and cleantech sector and frequently works with solar project developers on the sale of operating and development portfolios. 

In addition to his transactional work, Dan also has extensive experience advising public companies on compliance with United States federal securities laws, including public reporting, proxy solicitations and shareholder communications. Dan also advises private and public companies on governance related matters, including board composition and other good governance practices, drafting compliance policies and committee charters, ESG-related reporting, SEC filings and other disclosures. 

Dan’s clients benefit from his unique perspective of serving in-house prior to joining the firm in 2007. Dan was co-general counsel for a Virginia-based developer of systems, programs and training for a range of military and intelligence agencies. 

Dan is a co-editor of and frequent contributor to Foley Hoag’s IPO, Then What? Blog where he offers perspective and clarity around developments in the legal market for late stage and publicly traded companies.


  • College of William and Mary, J.D., 1999
  • Virginia Tech, B.S. in Biochemistry, 1996

Bar and Court Admissions

  • Massachusetts 
  • Virginia 


  • MDxHealth SA (Nasdaq/Euronext: MDXH), a foreign private issuer, in its acquisition of the OncoType DX Genomic Prostate Score business from Exact Sciences Corporation (Nasdaq: EXAS) for cash and equity consideration of up to $100 million, including a multi-year earn-out arrangement.
  • Novellus Therapeutics, a developer of novel medicines intended for the treatment of pediatric disease, in its sale to Brooklyn ImmunoTherapeutics (NYSE: BTX) for $125 million 
  • Computer-aided engineering company Exa Corporation (Nasdaq :EXA) in its $400M sale to French software company Dassault. 
  • Living Proof, Inc. in its acquisition by Unilever.
  • Applied Genetic Technologies Corporation, a Florida-based biotechnology company, in its initial public offering and subsequent follow-on offering.
  • Hittite Corporation in its sale to Analog Devices, Inc.
  • Llead investor in $75 million Series B financing of a pharmaceuticals company.
  • A healthcare information management company and its equity holders in $68.5 million sale to a strategic buyer.
  • Exa Corporation, a Massachusetts-based provider of software simulation tools, in its initial public offering.
  • Art Technology Group, a provider of e-commerce software, in its $1.0 billion sale to Oracle Corporation.
  • lLead investor in $55 million investment in development stage biopharmaceutical company.
  • Alere Inc., NYSE-listed medical device manufacturer, in private and public offerings of debt securities with an aggregate principal amount of $1.05 billion.